Vaping has an immunosuppressive effect, rendering the lung more susceptible to microbial infections
- Funded by National Institutes of Health (NIH)
- Total publications:0 publications
Grant number: 1R16HL178696-01
Grant search
Key facts
Disease
Bacterial infection caused by Klebsiella pneumoniaStart & end year
20242028Known Financial Commitments (USD)
$187,500Funder
National Institutes of Health (NIH)Principal Investigator
ASSISTANT RESEARCH PROFESSOR Rob OnyenwokeResearch Location
United States of AmericaLead Research Institution
NORTH CAROLINA CENTRAL UNIVERSITYResearch Priority Alignment
N/A
Research Category
Pathogen: natural history, transmission and diagnostics
Research Subcategory
Pathogen morphology, shedding & natural history
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable
Abstract
Project Summary/Abstract Respiratory disease carries a significant worldwide burden of morbidity and mortality. Currently it is well understood that tobacco smoking is a major cause of pulmonary/lung inflammation, which can progress onto pulmonary disease. However, significantly less is known about the effects of e-cigarettes (E-cigs) on the lung. Our study will assess whether vaped e-liquid (the actual product consumed/"vaped" by the E-cig user) exposure renders the lung more susceptible to pulmonary distress/disease using an ex vivo human bronchial epithelial cells (HBEC) model followed by our developed in vivo (C57BL/6J) lung injury model. We will also investigate the immune cell populations involved in any resultant lung injury. Hence, the goals of the current proposal are to model lung cell immune dysfunction using HBEC (Aim 1). To assess immune cell involvement/recruitment and lung pathology post-vape exposure using our in vivo model (Aim 2). We will then determine whether pre-exposure to e-liquid aerosol renders C57BL/6J mice more susceptible to pulmonary distress/disease using Klebsiella pneumoniae as a pathogen challenge model (Aim 3). Completion of the proposed Aims will ultimately shed light on the possible health implications of new and emerging tobacco products (such as E-cigs) and provide mechanistic detail on the possible initiation and progression of lung disease in E-cig users.